(Q35997955)

11 August 2017

1 reference

title

Economics of diabetes-cost impact of not treating diabetes early and intensively (English)

1 reference

11 August 2017

1

William Cefalu

1 reference

11 August 2017

publication date

1 January 2004

1 reference

11 August 2017

1 reference

11 August 2017

volume

6

1 reference

11 August 2017

issue

2

1 reference

11 August 2017

page(s)

51-60

1 reference

Banting lecture 1988. Role of insulin resistance in human disease

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980054-1

7 January 2021

The insulin resistance syndrome revisited

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980054-1

7 January 2021

Development of the multiple metabolic syndrome: an epidemiologic perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980054-1

7 January 2021

Cardiovascular morbidity and mortality associated with the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980054-1

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980054-1

7 January 2021

Insulin action and insulin resistance: diseases involving defects in insulin receptors, signal transduction, and the glucose transport effector system.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980054-1

7 January 2021

The importance of the beta-cell in the pathogenesis of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980054-1

7 January 2021

The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980054-1

7 January 2021

Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980054-1

7 January 2021

Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980054-1

7 January 2021

Obesity as the core of the metabolic syndrome and the management of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980054-1

7 January 2021

The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980054-1

7 January 2021

Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980054-1

7 January 2021

Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980054-1

7 January 2021

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980054-1

7 January 2021

PPARs and the complex journey to obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980054-1

7 January 2021

Economic costs of diabetes in the US in 2002.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980054-1

7 January 2021

The direct medical cost of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980054-1

7 January 2021

Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980054-1

7 January 2021

Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980054-1

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980054-1

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2804%2980054-1

7 January 2021

10.1016/S1098-3597(04)80054-1

Identifiers

DOI

1 reference

11 August 2017

1 reference